1. Home
  2. FOSL vs LRMR Comparison

FOSL vs LRMR Comparison

Compare FOSL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fossil Group Inc.

FOSL

Fossil Group Inc.

SELL

Current Price

$7.16

Market Cap

418.7M

ML Signal

SELL

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOSL
LRMR
Founded
1984
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
418.7M
455.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
FOSL
LRMR
Price
$7.16
$2.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$9.25
★ $14.40
AVG Volume (30 Days)
733.7K
★ 1.3M
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 25.26
N/A
EPS
★ N/A
N/A
Revenue
★ $1,004,406,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.39
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.70
$2.53
52 Week High
$7.33
$6.42

Technical Indicators

Market Signals
Indicator
FOSL
LRMR
Relative Strength Index (RSI) 69.18 16.38
Support Level $3.74 N/A
Resistance Level $7.33 $4.19
Average True Range (ATR) 0.38 0.20
MACD 0.05 -0.08
Stochastic Oscillator 88.98 0.29

Price Performance

Historical Comparison
FOSL
LRMR

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: